$Johnson & Johnson (JNJ.US)$ has been under pressure due to talc lawsuits alleging its talc products cause ovarian cancer. In May, the company proposed a $6.5 billion settlement to resolve these claims. Despite this, J&J remains a top dividend stock with a 3.37% yield and has increased its dividend for 62 consecutive years. It has a forward P/E ratio of 13.79 makes it undervalued compared to the broader market. However, the firm does have more than forty new products in late stage clinical trials...

$AIA (01299.HK)$ Another round of 1 mil shares repurchased on 3 Jun. Undervalued. Price still down. Opportunity???